Recombinant human activated factor VII is thrombogenic in a rabbit model of cyclic flow reduction and does not reduce intra-abdominal bleeding

Thrombosis and Haemostasis

Volumn 97, Issue 2, 2007, Pages 296-303

  Charbonneau, Sonia ^a   Girard, François ^a   Boudreault, Daniel ^a   Ruel, Monique ^a   Blais, Normand ^a   Hardy, Jean François ^a  

^a NOTRE DAME HOSPITAL   (Canada)

Author keywords

Arterial thrombosis; Hemorrhage; Recombinant activated human factor VII

Indexed keywords

FIBRINOGEN; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A; COAGULATING AGENT; RECOMBINANT PROTEIN;

ABDOMINAL BLEEDING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAROTID ARTERY INJURY; CAROTID ARTERY OBSTRUCTION; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; FIBRINOGEN BLOOD LEVEL; HEMATOCRIT; HYPERCOAGULABILITY; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RABBIT; RISK FACTOR; THROMBIN TIME; THROMBOCYTE COUNT; THROMBOELASTOGRAPHY; THROMBOGENESIS; ANIMAL; BLEEDING; BLOOD; BLOOD CLOTTING; BLOOD FLOW VELOCITY; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; HUMAN; LIVER; MALE; PATHOPHYSIOLOGY; RANDOMIZATION; SPLEEN; TIME;

ANIMALS; BLOOD COAGULATION; BLOOD FLOW VELOCITY; CAROTID ARTERY THROMBOSIS; CAROTID STENOSIS; COAGULANTS; DISEASE MODELS, ANIMAL; FACTOR VIIA; HEMATOCRIT; HEMORRHAGE; HUMANS; LIVER; MALE; PLATELET COUNT; RABBITS; RANDOM ALLOCATION; RECOMBINANT PROTEINS; SPLEEN; THROMBELASTOGRAPHY; TIME FACTORS;

EID: 33947509325     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-08-0429     Document Type: Article

References (46)

1. Stewart AJ, Hanley JP, Ludlam CA. Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor. Blood Coagul Fibrinolysis 1998; 9 (Suppl 1): S93-5.
2. Roberts HR. Clinical experience with activated factor VII: focus on safety aspects. Blood Coagul Fibrinolysis 1998; 9 (Suppl 1): S115-8.
3. Guillet B, Pinganaud C, Proulle V, et al. Myocardial infarction occurring in a case of acquired haemophilia during the treatment course with recombinant activated factor VII. Thromb Haemost 2002; 88: 698-699.
4. Peerlinck K, Vermylen J. Acute myocardial infarction following administration of recombinant activated factor VII (Novo Seven) in a patient with haemophilia A and inhibitor. Thromb Haemost 1999; 82: 1775-1776.
5. Aldouri M. The use of recombinant factor VIIa in controlling surgical bleeding in non-haemophiliac patients. Pathophysiol Haemost Thromb 2002; 32 (Suppl 1): 41-46.
6. Grounds M. Recombinant factor VIIa (rFVIIa) and its use in severe bleeding in surgery and trauma: a review. Blood Rev 2003; 17 (Suppl 1): S11-21.
7. Friederich PW, Henny CP, Messelink EJ et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003; 361: 201-205.
8. Karkouti K, Beattie WS, Wijeysundera DN, et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion 2005; 45: 26-34.
9. Raobaikady R, Redman J, Ball JA, et al. Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial. Br J Anaesth 2005;94:586-591.
10. Vanek T, Straka Z, Hrabak J, et al. Use of recombinant activated factor VII in cardiac surgery for an effective treatment of severe intractable bleeding. Jpn Heart J 2004; 45: 855-860.
11. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352: 777-785.
12. Folts J. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circulation 1991; 83: IV3-14.
13. Folts JD, Crowell EB, Jr., Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976; 54: 365-370.
14. Hill DS, Smith SR, Folts JD. The rabbit as a model for carotid artery stenosis and periodic acute thrombosis. Fed Proc 1987; 46: 421.
15. Samama CM, Bormin P, Bonneau M, et al. Comparative arterial antithrombotic activity of clopidogrel and acetyl salicylic acid in the pig. Thromb Haemost 1992;68:500-505.
16. Fattorutto M, Tourreau-Pham S, Mazoyer E, et al. Recombinant activated factor VII decreases bleeding without increasing arterial thrombosis in rabbits. Can J Anaesth 2004; 51: 672-679.
17. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899-909.
18. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 2005; 33: 883-890.
19. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005; 59: 8-15; discussion 18.
20. Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004; 127: 1123-1130.
21. Diprose P, Herbertson MJ, O'Shaughnessy D, et al. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized doubleblind placebo-controlled pilot study. Br J Anaesth 2005; 95: 596-602.
22. Lodge JF, Jonas S, Jones RM, et al. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl 2005; 11: 973-979.
23. Lodge JP, Jonas S, Oussoultzoglou E, et al. Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology 2005; 102: 269-275.
24. O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. J Am Med Assoc 2006; 295: 293-298.
25. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
26. Schreiber MA, Holcomb JB, Rojkjaer R. Preclinical trauma studies of recombinant factor VIIa. Crit Care 2005; 9 (Suppl 5): S25-8.
27. Schreiber MA, Holcomb JB, Hedner U, et al. The effect of recombinant factor VIIa, on coagulopathic pigs with grade V liver injuries. J Trauma 2002; 53: 252-257; discussion 7-9.
28. Schreiber MA, Holcomb JB, Hedner U, et al. The effect of recombinant factor VIIa on noncoagulopathic pigs with grade V liver injuries. J Am Coll Surg 2003; 196: 691-697.
29. Pusateri AE, Ryan KL, Delgado AV, et al. Effects of increasing doses of activated recombinant factor VII on haemostatic parameters in swine. Thromb Haemost 2005; 93: 275-283.
30. Martinowitz U, Holcomb JB, Pusateri AE, et al. Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries. J Trauma 2001; 50: 721-729.
31. Martinowitz U, Kenet G, Lubetski A, et al. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma. Can J Anesth 2002; 49: S15-20.
32. Martinowitz U, Kenet G, Segal E, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001; 51: 431-438.
33. Bell CR, Cox DJ, Murdock PJ, et al. Thrombelastographic evaluation of coagulation in transurethral prostatectomy. Br J Urol 1996; 78: 737-741.
34. Goobie SM, Soriano SG, Zurakowski D, et al. Hemostatic changes in pediatric neurosurgical patients as evaluated by thrombelastograph. Anesth Analg 2001; 93:887-892.
35. Samama CM, Thiry D, Elalamy I, et al. Perioperative activation of hemostasis in vascular surgery patients. Anesthesiology 2001; 94: 74-78.
36. Diness V, Bregengaard C, Erhardtsen E, et al. Recombinant human factor VIIa (rFVIIa) in a rabbit stasis model. Thromb Res 1992; 67: 233-41.
37. Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55: 638-648.
38. Friederich PW, Geerdink MG, Spataro M, et al. The effect of the administration of recombinant activated factor VII (NovoSeven) on perioperative blood loss in patients undergoing transabdominal retropubic prostatectomy: the PROSE study. Blood Coagul Fibrinolysis 2000; 11 (Suppl 1): S129-32.
39. Hendriks HG, Meijer K, de Wolf JT, et al. Effects of recombinant activated factor VII on coagulation measured by thromboelastography in liver transplantation. Blood Coagul Fibrinolysis 2002; 13: 309-313.
40. Telgt DS, Macik BG, McCord DM, et al. Mechanism by which recombinant factor VIIa shortens die aPTT: activation of factor X in the absence of tissue factor. Thromb Res 1989; 56: 603-609.
41. Yoshioka A, Nishio K, Shima M. Thrombelastgram as a hemostatic monitor during recombinant factor VIIa treatment in hemophilia A patients with inhibitor to factor VIII. Haemostasis 1996; 26 (Suppl 1): 139-142.
42. Keeney M, Allan DS, Lohmann RC, et al. Effect of activated recombinant human factor 7 (Niastase) on laboratory testing of inhibitors of factors VIII and IX. Lab Hematol 2005; 11: 118-123.
43. Murray D, Pennell B, Olson J. Variability of prothrombin time and activated partial thromboplastin time in the diagnosis of increased surgical bleeding. Transfusion 1999; 39: 56-62.
44. Kawaguchi C, Takahashi Y, Hanesaka Y, et al. The in vitro analysis of the coagulation mechanism of activated factor VII using thrombelastogram. Thromb Haemost 2002; 88: 768-772.
45. Tranholm M, Rojkjaer R, Pyke C, et al. Recombinant factor VIIa reduces bleeding in severely thrombocytopenic rabbits. Thromb Res 2003; 109: 217-223.
46. Sorensen B, Ingerslev J. Thromboelastography and recombinant factor VIIa-hemophilia and beyond. Semin Hematol 2004; 41: 140-144.